Gilder Gagnon Howe & Co. LLC Boosts Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Gilder Gagnon Howe & Co. LLC grew its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 5,636.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 404,237 shares of the company's stock after acquiring an additional 397,190 shares during the quarter. Gilder Gagnon Howe & Co. LLC owned about 1.06% of Tarsus Pharmaceuticals worth $22,383,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in TARS. Jennison Associates LLC boosted its stake in Tarsus Pharmaceuticals by 14.8% in the fourth quarter. Jennison Associates LLC now owns 2,500,132 shares of the company's stock valued at $138,432,000 after acquiring an additional 321,552 shares in the last quarter. Vanguard Group Inc. grew its holdings in Tarsus Pharmaceuticals by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 2,115,162 shares of the company's stock valued at $117,117,000 after purchasing an additional 17,839 shares during the last quarter. Lord Abbett & CO. LLC increased its position in Tarsus Pharmaceuticals by 115.2% during the fourth quarter. Lord Abbett & CO. LLC now owns 1,279,987 shares of the company's stock worth $70,873,000 after buying an additional 685,111 shares in the last quarter. Assenagon Asset Management S.A. grew its position in shares of Tarsus Pharmaceuticals by 0.5% in the fourth quarter. Assenagon Asset Management S.A. now owns 1,146,812 shares of the company's stock valued at $63,499,000 after purchasing an additional 5,565 shares during the period. Finally, Invesco Ltd. raised its stake in Tarsus Pharmaceuticals by 36.7% during the fourth quarter. Invesco Ltd. now owns 932,115 shares of the company's stock worth $51,611,000 after purchasing an additional 250,018 shares during the period. Institutional investors and hedge funds own 90.01% of the company's stock.

Tarsus Pharmaceuticals Stock Down 2.3 %

TARS traded down $1.21 during midday trading on Thursday, reaching $50.71. 303,576 shares of the company were exchanged, compared to its average volume of 692,199. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. The company's fifty day moving average price is $47.73 and its 200 day moving average price is $48.57. Tarsus Pharmaceuticals, Inc. has a one year low of $20.08 and a one year high of $57.28. The company has a market cap of $1.95 billion, a price-to-earnings ratio of -13.24 and a beta of 0.94.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.08. The firm had revenue of $66.41 million for the quarter, compared to analysts' expectations of $58.80 million. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. As a group, analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Insider Buying and Selling

In other news, insider Dianne C. Whitfield sold 2,315 shares of the company's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total transaction of $107,161.35. Following the transaction, the insider now owns 50,751 shares of the company's stock, valued at approximately $2,349,263.79. This represents a 4.36 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Bobak R. Azamian sold 7,131 shares of the firm's stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total transaction of $330,093.99. Following the transaction, the chief executive officer now directly owns 70,720 shares in the company, valued at $3,273,628.80. This trade represents a 9.16 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 32,542 shares of company stock worth $1,581,173 in the last three months. Insiders own 8.25% of the company's stock.

Wall Street Analyst Weigh In

TARS has been the subject of several analyst reports. HC Wainwright restated a "buy" rating and issued a $73.00 target price on shares of Tarsus Pharmaceuticals in a research note on Wednesday, February 26th. Guggenheim reiterated a "buy" rating and set a $78.00 price target (up from $75.00) on shares of Tarsus Pharmaceuticals in a research report on Monday, February 24th. Barclays lowered their target price on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. Jefferies Financial Group boosted their price target on Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a "buy" rating in a research report on Thursday, March 6th. Finally, Oppenheimer raised their price objective on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 22nd. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Tarsus Pharmaceuticals presently has an average rating of "Buy" and an average target price of $63.67.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.